ACS
CRSP icon

Archford Capital Strategies’s CRISPR Therapeutics CRSP Stock Holding History

Archford Capital Strategies’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-10
Closed – – 281
2019
Q2 		$0 Hold
10
– – ﹤0.01% 556
2019
Q1 		$0 Hold
10
– – ﹤0.01% 524
2018
Q4 		$0 Buy
+10
New +$348 ﹤0.01% 508

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Archford Capital Strategies's CRSP Position: Q3 2019 in Review

Archford Capital Strategies sold out of CRISPR Therapeutics (CRSP) in Q3 2019, closing a stake of 10 shares.

Archford Capital Strategies first reported a position in CRSP in Q4 2018 and held it in 3 quarters. The position peaked at $0 in Q2 2019. 182 funds tracked by Wall St. Rank hold CRSP as of Q3 2019.

  • Archford Capital Strategies reported no remaining CRISPR Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Archford Capital Strategies sold 10 CRISPR Therapeutics shares in Q3 2019.
  • Archford Capital Strategies first reported a position in CRISPR Therapeutics in Q4 2018 and held it in 3 quarters.
  • Archford Capital Strategies's CRISPR Therapeutics position peaked at $0 in Q2 2019.
  • 182 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2019.

Based on Archford Capital Strategies's 13F filing for Q3 2019, filed 23 Oct 2019.